BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...and COO, effective March 13, to become CEO at an undisclosed company. Rare disease company Pharming Group N.V....
...Staff Genmab A/S Tricida Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo Fisher Scientific Inc. Fujifilm Holdings Corp. NGM Biopharmaceuticals Inc. Pharming Group N.V. Horama...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BioCentury | Nov 13, 2019
Finance

Conjugate company Avidity preps for first dystrophy study with $100M series C

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund early clinical development of a...
BioCentury | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

...Pharming licenses Novartis autoimmune candidate Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG...
...for Regenerative Medicine (CIRM) City of Hope Harvard Medical School Johnson & Johnson Merck & Co. Inc. Mustang Bio Inc. Novartis AG Pharming Group N.V. Phosphoinositide...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Hematology, cancer, endocrine/ metabolic, musculoskeletal Adaptimmune Ltd. (NASDAQ:ADAP) $399.2 $529.2 TCR T cell therapies Cancer Pharming Group N.V....
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jan 29, 2019
Distillery Therapeutics

Cancer

INDICATION: Acute promyelocytic leukemia (APL); breast cancer Cell culture and mouse studies suggest liposomal co-delivery of the antioxidant quercetin and doxorubicin could help treat doxorubicin-resistant APL, breast cancer and other cancers. In doxorubicin-resistant human APL...
Items per page:
1 - 10 of 822
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...and COO, effective March 13, to become CEO at an undisclosed company. Rare disease company Pharming Group N.V....
...Staff Genmab A/S Tricida Inc. Akcea Therapeutics Inc. Refuge Biotechnologies Inc. GammaDelta Therapeutics Ltd. Thermo Fisher Scientific Inc. Fujifilm Holdings Corp. NGM Biopharmaceuticals Inc. Pharming Group N.V. Horama...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BioCentury | Nov 13, 2019
Finance

Conjugate company Avidity preps for first dystrophy study with $100M series C

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund early clinical development of a...
BioCentury | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

...Pharming licenses Novartis autoimmune candidate Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG...
...for Regenerative Medicine (CIRM) City of Hope Harvard Medical School Johnson & Johnson Merck & Co. Inc. Mustang Bio Inc. Novartis AG Pharming Group N.V. Phosphoinositide...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Hematology, cancer, endocrine/ metabolic, musculoskeletal Adaptimmune Ltd. (NASDAQ:ADAP) $399.2 $529.2 TCR T cell therapies Cancer Pharming Group N.V....
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jan 29, 2019
Distillery Therapeutics

Cancer

INDICATION: Acute promyelocytic leukemia (APL); breast cancer Cell culture and mouse studies suggest liposomal co-delivery of the antioxidant quercetin and doxorubicin could help treat doxorubicin-resistant APL, breast cancer and other cancers. In doxorubicin-resistant human APL...
Items per page:
1 - 10 of 822